Bassam Sonbol, Oncologist at Mayo Clinic Arizona, shared a post on X:
“CASSANDRA trial (The Lancet): Preoperative PAXG (gemcitabine, nab-paclitaxel, capecitabine, cisplatin) beats mFOLFIRINOX in resectable/borderline PDAC.
- Median EFS: 16 vs 10.2 mo (HR 0.63, p=0.0018)
- More neutropenia, but less neutopathy
- But significant number of EFS events gap is driven by the CA19-9 events (partof EFS definition in this study) OS immature (trending 32 vs 26 mo)
Should we switch? No, not yet—await mature OS and confirmation.”
More posts about PDAC.
